Athena Vision is an ocular therapeutics company developing novel gene-based therapies for retinal disorders that lead to vision loss. It has exclusive licences to intellectual property relating to several near-to-clinic gene-based therapies for conditions including Achromatopsia and X-linked Retinitis Pigmentosa. Athena Vision has also obtained an exclusive option to licence a further five programs in inherited retinal disease, age-related macular degeneration and uveitis.
Athena Vision is founded on the same expertise and leadership in translational and clinical research responsible for the world’s first gene therapy clinical trial in retinal disease. As a UK incorporated spin out company from UCL Business, Athena Vision is affiliated with one of the world’s highest-ranking universities, which along with partner Moorfields Eye Hospital, form one of the world’s largest ophthalmic research sites with the largest patient population in Europe or the USA.
Stuart Naylor was one of the initial group of founding project leads at Oxford BioMedica plc and as of 2008 sat on the Board as Chief Scientific Officer and Executive Director representing Scientific, Manufacturing, Clinical and Regulatory functions.
Stuart forged the instigation and development of the Company’s ophthalmology gene therapy pipeline through a combination of internal and external selling, in-licensing and multi-million pound fund-raising. He led a highly motivated team to secure three Investigational New Drug Applications within one year including the first ever to address the route cause of two significant retinal degenerative diseases: Stargardt's and Usher 1b. In June 2013 he incorporated Coltivare, a life sciences consultancy focusing on orphan, ‘vision-robbing’, retinal diseases.<
Robin Ali is Professor of Human Molecular Genetics at UCL Institute of Ophthalmology, London where he is Head of the Department of Genetics. He is also a Senior Researcher and the Theme Leader for Gene Therapy at NIHR Moorfields Biomedical Research Centre, holds a faculty position at UCL Institute of Child Health and is a Visiting Professor at Kellogg Eye Center, University of Michigan.
Robin and his award-wining research team are focused on the development of gene and cell therapies for the treatment of retinal disorders and are responsible for establishing the world’s first clinical trial of gene therapy for retinopathy and the first proof-of-concept for effective photoreceptor transplant.<
James Bainbridge is Professor of Retinal Studies at UCL Institute of Ophthalmology and a NIHR Research Professor at the NIHR Moorfields Biomedical Research Centre as well as a Consultant Ophthalmologist at Moorfields Eye Hospital. His programme of research extends from the laboratory investigation of mechanisms of disease in experimental models of sight loss to clinical trials of new medical and surgical interventions. He was the lead clinician in the world's first gene therapy trial for inherited blindness, demonstrating proof of-concept that offers hope for people with inherited retinal degeneration and lead on Europe's first clinical trial to transplant retinal cells derived from human embryonic stem cells to treat macular degeneration.
Michel Michaelides is Professor of Ophthalmology at UCL Institute of Ophthalmology and a Consultant Ophthalmic Surgeon at Moorfields Eye Hospital. His research is around improving the care and long-term outcomes for patients with retinal diseases with a particular interest in translational studies that link clinical research with laboratory findings, especially in the form of clinical trials for novel gene and cell therapy for sight loss.
Alexander Smith is a Senior Research Fellow in the Department of Genetics, UCL Institute of Ophthalmology responsible for the pre-clinical development of gene therapies for inherited retinal dystrophies. He was also one of the lead scientists on the world’s first gene therapy trial for inherited blindness.
Alexandria Forbes is President and CEO of MeiraGTx. Previously, she served as Senior Vice President of Strategic Operations and Chief Commercial Officer at Kadmon Corporation.
Prior to joining Kadmon in 2013, Alexandria spent 13 years as a healthcare investor at Sivik/Argus Partners and Meadowvale Asset Management. Alexandria was a portfolio manager responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics, and at Sivik/Argus Partners she managed the Global Life Science Fund, a long-biased fund focused on biotechnology. Before entering the hedge fund industry, Alexandria was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, she was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University. Alexandria received her PhD from Oxford University and her M.A. from Cambridge University.
Rich Giroux is Chief Operating Officer of MeiraGTx and brings 20 years of leadership and capital markets experience in finance and healthcare to his position. Prior to joining MeiraGTx, he was a partner at Sarissa Capital Management LP, an activist healthcare hedge fund. In 2010, Rich helped launch and operated Meadowvale Partners, a multi-strategy hedge fund, where he was a founding partner and healthcare portfolio manager. From 2001-2008, he was a partner at Sivik Global Healthcare (formerly Argus Partners), a long/short global equity healthcare fund. From 1996 to 2001, he worked in the equity derivative divisions of Goldman Sachs and Citigroup (formerly Solomon Smith Barney) where he structured, marketed and traded derivative and cash products for domestic and international hedge funds and asset allocators. Rich received his BA in Economics from Yale University in 1995.
Rachel joined UCL Business in 2009 as a Senior Business Manager, responsible for the Institute of Ophthalmology and Moorfields Eye Hospital. Prior to that she worked as the Intellectual Property Manager for the University of Leicester, where she managed, built value in and licensed the IP portfolio. In addition, Rachel negotiated commercial research contracts in biomedical and physical sciences, including commercial clinical trials. She also led the DTI Biotechnology Exploitation Platform Challenge project in the East Midlands. Rachel has a PhD in Cell Signalling and a postgraduate diploma in Marketing from the Chartered Institute of Marketing.
Athena Vision is focused on developing gene therapies for eye diseases based on research conducted at UCL (University College London)
LONDON, Tuesday 24 November 2015 – UCL Business PLC, the wholly-owned technology transfer company of UCL, today announced the formation of Athena Vision Limited, a biopharmaceutical company focused on the development of gene therapies to treat a range of devastating eye diseases causing blindness.
Athena has entered into a global partnership with MeiraGTx Limited to develop and commercialise Athena’s ocular gene therapy programmes arising from research conducted by Professor Robin Ali, Head of the Department of Genetics at the UCL Institute of Ophthalmology and a leader in the field of cell and gene therapy for the eye.
MeiraGTx, which is developing gene therapies for ocular diseases, neurodegenerative disorders and other diseases, will advance Athena’s pipeline of gene therapies through clinical trials to commercialisation. The partnership will pursue four initial clinical programmes in inherited retinal conditions: Leber congenital amaurosis type 2 (LCA2) caused by deficiencies in RPE65, achromatopsia caused by mutations in CNGB3 or CNGA3 and X-linked retinitis pigmentosa caused by mutations in RPGR. A Phase I/II dose-escalation clinical trial in LCA2 is expected to start in 1Q 2016. Development costs for all four programmes are supported by an undisclosed upfront payment by MeiraGTx.
Athena and MeiraGTx have unparalleled access to resources through their affiliation with the UCL Institute of Ophthalmology and its partner Moorfields Eye Hospital, which together form one of the world’s largest vision research centres, with access to a sizable and diverse patient population. The National Institute for Health Research (NIHR) Moorfields Biomedical Research Centre and Clinical Research Facility will support the translation of the partnership’s gene therapy programs from the laboratory to early-phase clinical testing.
The establishment of Athena accelerates the development of promising new therapies for inherited retinal diseases, which have been supported by the Medical Research Council (MRC), from early-stage research through clinical development via the MRC’s Developmental Pathway Funding Scheme (DPFS)
“With MeiraGTx, we have the necessary technology and critical mass to deliver a pipeline of novel therapeutics to change patients’ lives,” said Professor Ali, UCL Institute of Ophthalmology and Principal Founder, Athena.
“Athena’s leadership has expertise in developing advanced therapeutics from inception through clinical application. With MeiraGTx, we are building an integrated, global gene therapy business that brings together therapeutic and platform-based technologies along with extensive clinical, manufacturing and commercial experience,” said Stuart Naylor, CEO, Athena.
“This new rapid translation of world-leading science into clinical application and large inward investment to the UK highlights the importance of continued governmental support for scientific research,” said Professor Sir Peng Tee Khaw, Director of the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.
“We are delighted with such substantial investment to advance novel gene-based therapies. With the formation of this partnership, UK biomedical science continues to demonstrate its importance in the world sphere and, with sustained external and government support, our biomedical research leaders have true potential to bring to fruition innovations in treatment to benefit patients globally,” said Professor Philip J Luthert, Director, UCL Institute of Ophthalmology.
"The formation of Athena and the significant partnership with MeiraGTx provides a clear route for the translation and commercialisation of the world-class research strengths of Professor Robin Ali and his team at the UCL Institute of Ophthalmology. We look forward to supporting Athena as it commences its important work to deliver novel treatments to benefit patients with vision loss across the world," said Cengiz Tarhan, Managing Director of UCLB.
About Athena Vision Ltd
Athena is a biopharmaceutical company developing novel gene-based therapies for retinal disorders that lead to vision loss. Athena has exclusive licenses to intellectual property relating to several near-to-clinic gene-based therapies and also holds an exclusive option to license further gene therapy programmes in a wide range of ocular disorders.
Athena is founded on the same expertise and leadership in translational and clinical research responsible for the world’s first gene therapy clinical trial in inherited retinal disease. As a UK-incorporated spinout company from UCL’s Institute of Ophthalmology, Athena is affiliated with one of the world’s highest-ranking universities, which along with partner Moorfields Eye Hospital, form one of the world’s largest ophthalmic research sites. For further information, please visit www.athena-vision.com.
About MeiraGTx Limited
MeiraGTx Limited is developing gene therapy products for a range of inherited and acquired disorders for which there are no effective treatments available. MeiraGTx is focused on developing therapies for ocular diseases, including rare inherited blindness as well as xerostomia caused by radiation treatment for head and neck cancer and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). In addition, MeiraGTx has developed technology to regulate transgenes in vivo, which has the potential to transform the use of gene therapy and the delivery of biologic therapeutics. For further information, please visit www.meiragtx.com.
About UCL Institute of Ophthalmology
UCL Institute of Ophthalmology is one of the foremost eye and vision research institutes in the world. It operates at the cutting edge of translational research, delivering new therapies, diagnostic tools and preventive measures to patients suffering from visual impairment or blinding conditions. The combination of the Institute’s research resource with Moorfields Eye Hospital, which has the largest ophthalmic patient population in the western world, opens the way for further advances in vision research. Close collaboration with other academic partners and with industry extends its impact. The Institute is a recipient of a Queen's Anniversary Prize for Higher and Further Education, in recognition of outstanding research excellence. For further information, please visit www.ucl.ac.uk/ioo.
About NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology
The NIHR Moorfields Biomedical Research Centre was established in April 2007 and awarded a second five-year term by the NIHR from April 2012. Its purpose is to conduct translational research that is designed to take advances in basic medical research from the laboratory to the clinic, enabling patients to benefit more quickly from new scientific breakthroughs. The Centre is currently one of 11 Biomedical Research Centres that were awarded in 2012 to NHS/university partnerships with an outstanding international reputation for medical research and expertise, and experience of translating that research into the clinical setting. For further information, please visit www.brcophthalmology.org.
About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. For further information, please visit www.uclb.com.
Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. We are among the world’s top universities, as reflected by performance in a range of international rankings and tables. UCL currently has almost 29,000 students from 150 countries and in the region of 10,000 employees. For further information, please visit: www.ucl.ac.uk.
About National Institute for Health Research
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, please visit www.nihr.ac.uk.
About Medical Research Council
The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. For further information, please visit www.mrc.ac.uk.
For further information or to arrange an interview contact Margaret-Anne Orgill, Media Relations Manager, UCL Enterprise; M: +44(0)77572 602345, E: email@example.com.